A Multi-Centre Randomised Clinical Trial of Biomarker-Driven Maintenance Treatment for First-Line Metastatic Colorectal Cancer (MODUL)
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Capecitabine (Primary) ; Vemurafenib (Primary) ; Cetuximab; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms MODUL
- Sponsors Roche
- 30 Aug 2017 Planned number of patients changed from 1682 to 1400.
- 30 Aug 2017 Planned End Date changed from 1 Feb 2019 to 30 Oct 2020.
- 30 Aug 2017 Planned primary completion date changed from 1 Feb 2019 to 30 Oct 2020.